Related Experiment Video
Updated: Feb 27, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Distinct proteome pathology of circulating microparticles in systemic lupus erythematosus
Ole Østergaard1, Christoffer Tandrup Nielsen2, Julia T Tanassi1
1Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark.
Background:
The pathogenesis of systemic lupus erythematosus (SLE) is poorly understood but has been linked to defective clearance of subcellular particulate material from the circulation. This study investigates the origin, formation, and specificity of circulating microparticles (MPs) in patients with SLE based on comprehensive MP proteome profiling using patients with systemic sclerosis (SSc) and healthy donors (HC) as controls.
Methods:
We purified MPs from platelet-poor plasma using differential centrifugation of samples from SLE (n = 45), SSc (n = 38), and two sets of HC (n = 35, n = 25). MP proteins were identified and quantitated after trypsin digestion by liquid chromatography-tandem mass spectrometry. The abundance of specific proteins was compared between the groups using univariate statistics and false discovery rate correction for multiple comparisons. Specific proteins and protein ratios were explored for diagnostic and disease activity information using receiver-operating characteristic curves and by analysis of correlations of protein abundance with disease activity scores.
Results:
We identify and quantitate more than 1000 MP proteins and show that a subpopulation of SLE-MPs (which we propose to call luposomes) are highly specific for SLE, i.e. not found in MP preparations from HC or patients with another autoimmune, systemic disease, SSc. In SLE-MPs platelet proteins and mitochondrial proteins are significantly diminished, cytoskeletal proteins deranged, and glycolytic enzymes and apoptotic proteins significantly increased.
Conclusions:
Normal MPs are efficiently removed in SLE, but aberrant MPs, derived from non-lymphoid leukocytes, are less efficiently removed and abundantly produced leading to an altered MP proteome in SLE. The data suggest that an abnormal generation of MPs may partake in the pathology of SLE and that new diagnostic, monitoring, and treatment strategies targeting these processes may be advantageous.
Insights
Systemic lupus erythematosus (SLE) involves abnormal microparticle (MP) production and clearance. These aberrant MPs, termed luposomes, are specific to SLE and may contribute to disease pathology, offering new diagnostic and therapeutic targets.
Area of Science:
- Immunology
- Proteomics
- Pathology
Background:
- Systemic lupus erythematosus (SLE) pathogenesis is unclear, potentially involving impaired clearance of circulating subcellular material.
- Microparticles (MPs) are implicated in SLE, but their origin, formation, and specificity require detailed investigation.
Purpose of the Study:
- To investigate the origin, formation, and specificity of circulating MPs in SLE patients.
- To perform comprehensive proteome profiling of MPs in SLE, systemic sclerosis (SSc), and healthy controls (HC).
Main Methods:
- Purification of MPs from platelet-poor plasma using differential centrifugation.
- Identification and quantitation of MP proteins via liquid chromatography-tandem mass spectrometry.
- Statistical comparison of protein abundance and correlation with disease activity scores.
Main Results:
- Over 1000 MP proteins identified; a specific subpopulation, 'luposomes', is unique to SLE.
- SLE MPs show diminished platelet and mitochondrial proteins, deranged cytoskeletal proteins, and increased glycolytic and apoptotic proteins.
- Aberrant MPs are abundantly produced and less efficiently cleared in SLE patients.
Conclusions:
- Abnormal MP generation and clearance contribute to SLE pathology.
- The unique proteome of SLE-derived MPs (luposomes) suggests potential as diagnostic biomarkers.
- Targeting aberrant MP generation and clearance may offer novel therapeutic strategies for SLE.

